2cureX AB (publ) (STO:2CUREX)

Market Cap	49.60M +175.2%
Revenue (ttm)	1.98M -49.7%
Net Income	-26.35M
EPS	-1.50
Shares Out	25.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.08 (4.20%)
Ex-Dividend Date	Jun 27, 2025

Volume	34,441
Average Volume	191,102
Open	1.958
Previous Close	1.976
Day's Range	1.880 - 1.974
52-Week Range	0.514 - 5.520
Beta	3.03
RSI	57.61
Earnings Date	May 21, 2026

About 2cureX AB

2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 14
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: 2CUREX

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.